# Antarka

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antarka

- Industry: Biotechnology
- Headquarters: Montevideo, Uruguay
- Website: www.antarka.bio/
- Total disclosed funding: $3.5M
- Latest round: Seed (Mar 7, 2026)
- Investors on record: 5

## About

Antarka, founded in 2023, specializes in advanced skincare solutions using proprietary enzymes derived from Antarctic organisms to repair UV-induced skin DNA damage, enhancing skin health and appearance.Antarka is a biotechnology company based in Montevideo, Uruguay, established in 2023. It focuses on developing innovative skincare products that incorporate a unique enzyme designed to repair skin damage. The company has not undergone any significant pivots or changes in strategy since its inception. Antarka was founded by individuals with a vision to leverage unique biological resources for skincare advancements. Notably, the company completed its SEED funding round raising USD 3.50 mn on March 7, 2026, with investors including CTK, Inc, GS Futures, Natura Ventures, SOSV, and Zentynel Frontier Investments, marking its total amount raised to USD 3.50 mn.Antarka's primary offering is a proprietary enzyme developed from organisms found in Antarctica, designed to repair UV-induced skin DNA damage at the molecular level. This enzyme is incorporated into a range of skincare products, including advanced anti-aging creams, high-performance sunscreens, deep-repair creams, and skin repair serums. The enzyme is marketed as safe for topical use and has undergone rigorous safety evaluations, with early clinical studies demonstrating its effectiveness in enhancing skin elasticity, firmness, and overall appearance. Antarka's products are aimed at end users who are seeking innovative solutions for skin aging and damage repair. The company targets both B2B partnerships with cosmetic brands for formulation integration and direct consumer markets, with a footprint in regions including North America and South America.Antarka generates revenue through partnerships with cosmetic brands and direct sales to consumers, utilizing a B2B and B2C transaction structure. The company's flagship product, the enzyme serum, is central to its offerings and is likely bundled in various formulations for retail distribution. Revenue streams are influenced by collaboration agreements with companies looking to incorporate Antarka's enzyme into their skincare lines, as well as direct purchases from consumers who access these products through the company's website or approved retailers. While specific pricing plans for these products have not been disclosed, the business model suggests a blend of one-time purchases and potential subscription services for ongoing consumer engagement.In March 2026, Antarka raised USD 3.50 mn in SEED funding to enhance its scientific and business teams, boost manufacturing capabilities, and support ongoing research efforts in preparation for a wider market launch. The company aims to release new products incorporating its proprietary enzyme in the coming years, with plans to expand into additional markets in Europe and Asia by 2027. This funding will facilitate the growth of Antarka's operations and extend its reach into new geographic regions.

## Funding rounds

- Seed, Mar 7, 2026, $3.5M — SOSV, CTK, Inc, GS Futures, Zentynel Frontier Investments, Natura Ventures

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- CTK, Inc — Seed
- GS Futures (https://capitalatlas.ai/funds/gs-futures) — Seed
- Zentynel Frontier Investments (https://capitalatlas.ai/funds/zentynel-frontier-investments) — Seed
- Natura Ventures — Seed